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Background: Many countries have started screening and prevention programs for chronic kidney disease (CKD).
However, one of the main concerns of health authorities is whether management strategies for diagnosed CKD
patients can decrease mortality or morbidity. This study aimed to investigate the effect of two competing clinical
strategies of treatments under nephrologists’ supervision compared with no treatment on the frequency of the
need to start renal replacement therapy (RRT) and mortality in CKD patients.
Methods: Our cohort comprised consecutive newly diagnosed patients with CKD in an outpatient clinic in Tehran
between October 2002 and October 2011. CKD Patient enrollment occurred if two criteria of high plasma creatinine
level and chronicity of renal disease by at least 3 months of clinical history or small sized kidneys in ultrasound
findings were met. Demographic data and time of RRT or mortality in patients who had been followed up regularly
were compared with those in the control group. The control group included those patients who did not attend a
nephrology clinic to receive CKD management package for at least 1 year during the study period.
Results: The cohort included 76 patients in the control group and 389 patients in the supervised group. The mean
age of the patients was 61.33±14.9 years (16–95 years). The ratio of males/females was 1.47 (277/188). The mean
follow-up in the control and supervised groups was 33.29±20.50 (7–111) and 36.03±25.24 (6–124) months ,
respectively, and the total patient years of follow-up was 1382.3. A substantial number of patients survived without
RRT until the first year of follow up (96%) in both groups, but afterward, those in the control group had more
deaths or need to start RRT in comparison with those who received medical advice (20 vs. 67 months; p= 0.029).
This cohort also showed a higher survival and a longer time to show a GFR of less than 15 cc/min (84 vs 34
months, p<0.0001) in patients who had been under physician supervision compared with the control group.
Conclusions: Active follow-up of CKD patients appears to significantly decrease the risk of death or progression to
end-stage renal disease and the requirement to start renal replacement therapy.Background
The incidence and prevalence of end-stage renal disease
(ESRD), which is not restricted to the developed world,
is escalating. It is estimated that 80% of death due to
chronic diseases is in developing countries, and 70% of
the ESRD population will be found in this part of the
world by 2030 [1-3]. The cost of renal replacement* Correspondence: mmahdavi@tums.ac.ir
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distribution, and reproduction in any mediumtherapy (RRT) is huge, even in wealthy countries, such
as the United States, where the ESRD population con-
sumes 6-7% of the Medicare budget [3,4]. Similarly, in
Taiwan, ESRD patients, which comprise 0.23% of the
population, are allocated 7.2% of health-care resources.
[5]It has also been shown that each month of dialysis in
Iran costs at least 1000 USD [6].
International efforts through numerous campaigns
such as World Kidney Day have made the medical com-
munity aware of the common frequency of chronic kid-
ney disease (CKD), its strong association with diabetes,
and higher attributed mortality [7]. Because screening
without follow-up is of little use, many countries haved Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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increasing burden, which is mainly due to higher prema-
ture mortality and disability because of progression to
ESRD [5,8-10]. However, one of the main concerns of
health authorities is the quantitative effect of medical
care of detected CKD patients after diagnosis in post-
poning or prevention of these outcomes.
The current cohort study aimed to determine if
provision of a management program, including health
education, diet modification, and pharmacological treat-
ment through nephrology clinics for CKD patients, is
able to reduce mortality and the need for RRT.Patients & methods
Our study sample comprised all newly diagnosed
patients with CKD consecutively admitted to the
authors' out-patient nephrology office or clinic in
Tehran between October 2002 and October 2011. These
patients were admitted of their own will for different
reasons, or admission was based on recommendation of
another physician. There were two renal outpatient
clinics that offered diagnostic and follow-up services to
patients with renal disease by just one responsible neph-
rologist (author,M.Mahdavi-Mazdeh). CKD patient en-
rollment took place if there were at least two separate
calculated estimated glomerular filtration rate (eGFR)
between 15 and 60 mL/min/1.73 m2 by serum creatinine
and chronicity, determined by more than 3 months of
clinical history or small sized kidney in ultrasound.
Patients who did not complete their follow-up for at
least 6 months were excluded from analysis.
To compare the effect of two clinical strategies of
medical supervision and no treatment on the need to
start RRT and/or mortality rate, two groups were
defined. The first group included those patients who had
been followed up regularly (389 patients) and the second
group was the control group who did not attend the
nephrology clinic for at least 1 year (76 patients). There-
fore, we did not use an unethical approach to prevent
some patients from receiving treatment. Finally, those
patients followed up regularly (at least once every 6
months) were compared with those who failed to be
followed up as frequently. If a patient did not attend
the clinic for more than 1 year, he/she was included in
the control group. Otherwise, those patients who used
the prescriptions but attended the clinic with less fre-
quent intervals, were included in the treated group.
Visits were scheduled according to each patient’s clin-
ical setting, but were carried out at least every 6 months.
During each visit, patients were monitored for body
weight, blood pressure, serum creatinine levels, fasting
plasma glucose levels, lipid profile, calcium, phosphorus,
hemoglobin (Hb), and other parameters. All laboratoryvariables were collected in all patients for clinical
purposes.
A total number of 465 patients were enrolled. The end
points of the study were defined as time to RRT, time to
GFR less than 15cc/min/m2, and time to death or reach-
ing the deadline of data collection for the first step of
analysis.
The treatment program consisted of drugs for blood
pressure, bone mineral metabolism indices, and
hemoglobin control. Vaccination for Hepatitis B virus
according to each patient situation was scheduled. The
two main parts of each visit apart from routine prescrip-
tion were: (1) nutritional consultation regarding salt and
water restriction, phosphate content of different foods,
and protein consumption: and (2) checking for treat-
ment compliance of patients with their accompanying
persons (usually first degree relatives) and some advice
to increase the compliance of patients. The goals of
treatment protocols were based on Disease Outcomes
Quality Initiative (KDOQI) guidelines. The routine
protocol for anemia management in Iran includes re-
combinant α-erythropoietin and iron sucrose for intra-
vascular iron and other different forms for the oral
route. The α-erythropoietin was not covered by insur-
ance agencies in the first 3 years of study, but after this
time, those who required the drug could purchase it at a
reasonable price. The phosphate binder was calcium
carbonate. The main antihypertensives for all patients,
except those with complications, were angiotensin-
converting-enzyme inhibitors/angiotensin receptor block-
ers. All patients were advised to be vaccinated against
Hepatitis B virus, and antibody titer was checked in fol-
lowing visits. Arteriovenous fistula was recommended for
patients who were anticipated to need dialysis in the fol-
lowing 6–12 months.
Statistical analysis
Descriptive data at the first assessment and follow-up
are presented as mean± SD. Continuous and categorical
variables were compared between the two groups by
using the independent samples t-test and Pearson chi-
squared test. Clinical end points were compared between
groups by conducting survival analysis. Multivariate
adjusted relations were evaluated by using the Cox pro-
portional hazard model. All statistical analyses were per-
formed by SPSS statistical package, version 16.0 (SPSS,
Inc., Chicago,IL). A p less than 0.05 from 2-sided tests
was considered significant.
Results
This cohort study included 465 newly diagnosed adult
CKD patients who had been visited in the clinic for at
least 6 months (Figure 1). The mean age of patients was
61.33±14.9 years (16–95 years). The ratio of males/
Figure 1 Kaplan-Meier estimated survival curves. Patients who were under medical supervision (n=389) showed a higher survival and longer
time to achieve a eGFR of less than 15 cc/min compared with those who were not under medical observation (n=76) (34 vs 84months),
according to the Log Rank test significance level (p<0.0001). Supervised patients also had less need for RRT and less death compared with
controls (20 vs. 67months) (P = 0.029).
Table 1 Demographic and endpoint data of the two groups
Group1 Group2 P value
Control group (76) treated group (389)
CKD stage number(percent) 0.99
3a:60>GFR≥45 14(18.4) 140(36.0)
3b:45>GFR≥30 number(percent) 35(46.1) 180(46.3)
4:30>GFR≥15 number(percent) 27(35.5) 69(17.7)
(GFRcc/min/1.73m2)




GFRcc/min/1.73m2 mean±SD 35.09±10.56 (38+7)/140(32.1) 0.753
Age(years) mean±SD 56.5±17.3 62.3±14.2 0.008*
Diabetes mellitus 23(30.3%) 130(33.4%) 0.328
Sex(Male/Female) 43/33=1.3 234/155=1.5 0.324
Anemia(Hb<11gr/dl) 13/48 42/203 0.218
Systolic HTN(>14CmHg) 32/60 113/312 0.010*
Systolic Blood pressure (CmHg) mean±SD 14.91±2.85 13.82±2.68 0.005*
Diastolic Blood pressure (CmHg) mean±SD 8.34±1.47 7.74±1.30 0.001*
Hemoglobin(gr/dl) mean±SD 12.58±2.51 12.61±2.03 0.913
Calcium(mg/dl) mean±SD 9.12±0.70 9.22±1.00 0.681
Phosphorus(mg/dl) mean±SD 4.30±1.07 4.04±0.77 0.348
Uric acid(mg/dl) mean±SD 7.45±1.84 9.46±12.84 0.549
Cholesterol(mg/dl) mean±SD 209.56±57.66 196.19±69.14 0.251
Triglyceride(mg/dl) mean±SD 266.14±181.11 192.40±119.00 0.048
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follow-up was 1382.3. Overall, 13 patients died (1.1/100
person-years) and 71 patients started RRT (5.1/100
person-years) in the cohort (Table 1).
Baseline data
The baseline data of patients are summarized in Table 1.
The frequency of different CKD stages or diabetes as the
cause of CKD was similar between the two groups.
However, the mean age of patients with medical super-
vision was higher than that in the control group
(62.3±14.2 vs 56.5±17.3 years, p=0.008). Mean systolic
and diastolic blood pressure were higher in the control
group than those in the supervised group.
Follow-up data
Mean follow-up in the control group and supervised
group was 33.29±20.50 months (7–111 months) and
36.03±25.24 months (6–124 months), respectively. The









Systolic Blood pressure(Cm Hg)
1st year 14.01±2.14 (53)
2nd year 14.18±2.04 (40)
3rd year 14.10±2.29 (31)
4th year 14.49±2.17 (21)
5th year 15.14±1.95 (7)
Diastolic Blood pressure(Cm Hg)
1st year 7.88±1.16 (53)
2nd year 8.07±1.26 (40)
3rd year 8.15±1.30 (31)
4th year 8.08±1.25 (21)






5th year 4.57±1.19(7)was 28 and 29 months, respectively. The laboratory data
during the follow up period is presented for comparison
between the two groups (Table 2).In both groups, a sub-
stantial number of patients survived without RRT after 1
year (96%).However, over time, the percentage of those
who did not receive medical surveillance suffered more
death or needed to start RRT compared with those
who received medical service (26.3% vs 17.2%,p=0.048).
Figure 1 and Table 3 show the outcomes of the entire
cohort, grouped according to the stage of CKD. Five
patients died during the first 2 years of follow up.
Changes in mean blood pressure, hemoglobin and phos-
phate during follow-up are shown in Table 2. We
observed that hypertension control and higher
hemoglobin levels were achieved in those under medical
supervision. Similarly, HBV vaccination rate in them was
higher than the control group (76.8% vs 23.7%,
p<0.0001).
By Cox proportional hazard model, we found that the
only significant baseline predictor for the need for RRTgroups






















Table 3 Survival table















Estimated time ± SE Estimated time ± SE
11 0.960±0.023 3/0 70 11 0.968±0.009 10/2 341
22 0.925±0.033 4/1 51 23 0.899±0.017 29/4 236
38 0.762±0.063 10/2 27 38 0.840±0.022 38/8 155
50 0.588±0.093 14/2 10 50 0.813±0.025 41/9 99
64 0.504±0.111 15/2 6 62 0.754±0.035 44/11 55
70 0.336±0.122 16/3 4 71 0.698±0.045 47/11 35
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and hemoglobin, triglycerides and age were not signifi-
cant parameters.
Discussion
One of the main concerns of efficacy of CKD screening
programs is the effect of follow-up on decreasing the
speed of disease or preventing its inevitable, mainly car-
diovascular complications. Our cohort showed a signifi-
cantly higher survival and a longer time to show a eGFR
of less than 15 cc/min in patients who had been under
physician supervision compared with those without
supervision. Supervised patients also had less need of
RRT and less death compared with the control group.
Our study confirmed that by using cheap diagnostic
tests, characteristics that may predict RRT can be deter-
mined and controlled with simple clinical strategies [11].
It appears that if patients are observed by nephrologists
or possibly internists, the rate of decline of kidney func-
tion can be slowed and the potential negative conse-
quences of the disease for the individual and the health
system can at least be postponed. In our study, we used
the maximum level of non-compliance of patients as not
referring to a physician for more than 1 year, which was
equal to taking less treatment than those who visited
their physician regularly, and evaluated its effect on out-
come during the cohort. As expected, patient survival
was similar at 96% in both groups in the first year. The
probability of mortality increases with a decrease in GFR
and the accumulated amount of toxic agents over time,
which emphasizes the slow nature of the disease and
asymptomatic early stages of CKD.
Interestingly, in our study the mortality rate was lower
than that in many other studies, including Johnson et al.,
which found 11.4 deaths/100 person-years and 1.6 pro-
gressions to RRT/100 person-years.[11] The reason for
this difference between studies may be the higher num-
ber of old patients in the previous study (56.3% versus
14% older than 75 years). Different methods of patient
referral to nephrologists can play a role in difference inoutcome. In Iran, a patient who is informed of a kidney
problem by the physician can choose to seek advice dir-
ectly from a nephrologist or go to a family physician or
even ignore it. It appears that some patients die before
reaching ESRD, the destination of CKD road. In agree-
ment with this possibility is the age distribution of
patients who initiate RRT in Iran. According to the
ESRD registry, the mean age of men and women who
started RRT was 52.5 years and 53.0 years in 2006, re-
spectively, which is lower than many other countries
with similar situation [12].
Levin et al. found that in a retrospective cohort of a
provincial registry database of patients with an eGFR less
than 30 cc/min/1.73 m2 (4231 patients) with access to
medical services and a median follow-up of 31 months,
there was large heterogeneity of outcome (death or start
of RRT). Seventy-six percent of patients with rapid pro-
gression (annual eGFR change >5 cc/min/1.73 m2)
started RRT but 27% of those with a slower decrease in
eGFR started RRT. Interestingly, the authors showed
higher systolic blood pressure and phosphorus levels,
and lower calcium and albumin levels were associated
with a rapid progression and time to RRT by multivari-
ate analysis [13]. We conclude that managing the above-
mentioned variables is important among those who are
under medical supervision compared with those without
any follow-up.
In a meta-analysis of 13 studies, as part of the process
of CKD prognosis collaboration in the KDIGO confer-
ence on CKD controversies, a stronger association of
lower eGFR with ESRD than mortality was found. The
hazard ratios for ESRD in patients with a GFR of 30–44
cc/min/1.73 m2 (2.72; 95% CI: 1.29-3.37) and a GFR of
15–29 cc/min/1.73 m2 (10.21; 95% CI: 8.36-12.46) were
significantly higher compared with that for a GFR of
45–74 cc/min/1.73 m2. Similar statistics for mortality in
the latter two groups were 1.35 (1.23-1.49) and 2.25
(1.81-2.79), respectively [14]. An independent association
of a lower eGFR with ESRD, all-cause mortality, and the
risk of cardiovascular mortality has been confirmed
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changes over time, the efficacy and components of treat-
ment, and patients' compliance were not considered for
analysis.
The current study found that treated patients with
earlier stage of CKD(3a), reached endpoint (32.1%) more
than control group(21.4%) , which may raise the issue of
generalization, but we speculate that overlapping of the
two outcomes of RRT and death is the main reason for
this difference. The percentages of those who reached
ESRD in stage 3a in both groups of control and treated
group were 21.4% versus 21.7% (Table 1). The death rate
was higher in the treated group compared with the rate
in the control group, which was mainly caused by higher
age of patients in the treated group.
Study limitations
The wide standard deviation of the mean follow-up in the
groups (33.29±20.50 [7–111] and 36.03±25.24 [6–124]
months) was a limitation of the study, which may have
had a negative effect on the internal validity of analysis.
Another important point in considering the results is the
higher portion of CKD stage 4 in the control group. Al-
though this was not statistically significant, it may theoret-
ically have increased the rate of those who reached ESRD.
Furthermore, the mean age in the supervised group was
significantly higher than that in the control group, which
may have increased the occurrence of death.
Conclusions
In conclusion, the results of this study show that super-
vision through nephrology clinics with some inexpensive
protocols in patients, who desire to use such facilities,
may benefit from a decrease in the rate of mortality, as
well as postponement of the need for RRT.
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